Table 3.

Plasma IL-8 and ICOSLG and Patient Characteristics for Patients With Newly Diagnosed GBM

Plasma Biomarkers and Patient Characteristics	Plasma IL-8			Plasma ICOSLG
	Ratioa	95% CI	P b	Ratioa	95% CI	P b
MGMT  Met vs Non-met	1.07	0.85–1.36	.55	0.92	0.85–1.01	.065
Age (years)  Per 10 years	1.16	1.05–1.29	.0038	0.97	0.94–1.01	.18
Sex  F vs M	0.92	0.73–1.16	.50	0.91	0.83–0.98	.019
Treatment  None/RT/TMZ vs Stuppc	1.44	1.13–1.83	.0035	0.93	0.85–1.02	.10

Bold values represent P < .05. CI, confidence interval; F, female; GBM, glioblastoma; ICOSLG, ICOS ligand; IL-8, interleukin-8; M, male; Met, methylated; Non-met, non-methylated; RT, radiotherapy; TMZ, temozolomide.

^aRatio of plasma biomarker level between categories for each variable.

^bA general linear model was used to evaluate association between plasma protein levels and categorical variables.

^cTreatment regimens were dichotomized into no treatment, radiotherapy only and temozolomide only versus Stupp’s regimen (radiotherapy, concomitant and adjuvant temozolomide) and radiotherapy with concomitant temozolomide.